Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Nephrology
Renal Failure Clinical Trials
A listing of Renal Failure medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Anniston : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Birmingham : University of Alabama at Birmingham
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Birmingham : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Huntsville : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Mobile : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
Montgomery : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Arizona
Goodyear : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Peoria : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Phoenix : Mayo Clinic Arizona
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Phoenix : Banner Good Samaritan Medical Center/Liver Disease Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Phoenix : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
Tempe : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Tucson : University of Arizona Medical Center South Campus
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Tucson : University of Arizona Liver Research Institute
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
California
Alhambra : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Anaheim : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Azusa : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Bell Gardens : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Beverly Hills : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
Cerritos : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Chula Vista : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Colton : Arrowhead Regional Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Coronado : SCTI Research Foundation
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
East Los Angeles : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Fountain Valley : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Fullerton : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Garden Grove : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Granada Hills : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Huntington Beach : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Inglewood : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
La Jolla : Scripps Clinic
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
La Mesa : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Laguna Hills : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Lakewood : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Lancaster : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Lomita : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Los Angeles : USC University Hospital
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Los Angeles : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Los Angeles : Clinical Investigative Site 006
Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)
Lynwood : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Mission Hills : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Northridge : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Orange : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Redondo Beach : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Riverside : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Sacramento : UC Davis Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Sacramento : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
San Diego : Clinical Investigative Site 000015
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
San Diego : Veteran's Administration Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
San Diego : Clinical Investigative Site 1049
Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)
San Francisco : Clinical Investigative Site 000012
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
San Francisco : California Pacific Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Whittier : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Yuba City : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Colorado
Aurora : Clinical Investigative Site 00004
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Aurora : University of Colorado Denver
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Aurora : Clinical Investigative Site 007
Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)
Westminster : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Connecticut
Hartford : Hartford Hospital
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Middlebury : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
New Haven : Yale University School of Medicine
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
New Haven : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
New Haven : Clinical Investigative Site 005
Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)
View More »
North Haven : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
District of Columbia
Washington : Georgetown University Hospital
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Washington : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Florida
Boynton Beach : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Coral Springs : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Daytona Beach : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Hollywood : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Hudson : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
Jacksonville : Mayo Clinic
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Jacksonville : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Jacksonville Beach : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Lauderdale Lakes : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Melbourne : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Miami : University of Miami
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Miami : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Miami Beach : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
New Port Richey : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Pembroke Pines : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Port Charlotte : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Summerfield : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Tampa : Clinical Investigative Site 000002
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Tampa : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Georgia
Atlanta : Emory University Hospital
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Atlanta : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Augusta : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Canton : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Macon : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
Newnan : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Hawaii
Honolulu : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Idaho
Meridian : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Illinois
Chicago : Northwestern University
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Chicago : University of Chicago
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Chicago : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Evanston : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Maywood : Loyola University Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
View More »
Peoria : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Quincy : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Indiana
Columbus : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Indianapolis : Indiana University Health - University Hospital
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Michigan City : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Iowa
Ames : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Iowa City : Iowa City VA Health Care System
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Kansas
Kansas City : University of Kansas Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Kansas City : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Wichita : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Kentucky
Lexington : Clinical Investigative Site 000005
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Lexington : University of Kentucky Chandler Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Lexington : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Lexington : Clinical Investigative Site 004
Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)
Louisville : University of Louisville
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Louisiana
Baton Rouge : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Lafayette : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Metairie : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Natchitoches : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
New Orleans : Tulane Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
View More »
Ruston : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Shreveport : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Maine
Rockport : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Maryland
Baltimore : University of Maryland
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Bethesda : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Oxon Hill : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Massachusetts
Boston : Beth Lsrael Deaconess Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Burlington : Lahey Clinic Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Plymouth : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Springfield : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Worcester : University of Massachusetts Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Michigan
Ann Arbor : Clinical Investigative Site 000009
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Detroit : Henry Ford Hospital
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Detroit : Detroit Medical Center
Fondaparinux in Critically Ill Patients With Renal Failure
Detroit : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Flint : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
Grand Rapids : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Kalamazoo : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Midland : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Pontiac : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Royal Oak : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Southgate : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Minnesota
Minneapolis : University of Minnesota
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Minneapolis : Clinical Investigative Site 008
Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)
Mississippi
Columbus : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Gulfport : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Missouri
Kansas City : Saint Luke's Hospital
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Kansas City : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
St. Louis : Saint Louis University
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
St. Louis : Washington University School of Medicine
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
St. Louis : Clinical Investigative Site 003
Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)
View More »
St. Peters : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Nebraska
Lincoln : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
North Platte : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Omaha : University of Nebraska Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Nevada
Henderson : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Las Vegas : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
New Jersey
Livingston : Clinical Investigative Site 000010
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Livingston : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Toms River : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Voorhees : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
New York
Bronx : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Buffalo : Clinical Investigative Site 000011
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Buffalo : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Flushing : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Great Neck : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
Mineola : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
New York : Clinical Investigative Site 00006
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
New York : Bellevue Hospital
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
New York : Columbia University Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
New York : NYU Langhorn Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
New York : Mount Sinai Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
New York : Yorkville Dialysis Center
Sorbent Treatment Prescriptions Pilot Study
Orchard Park : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Rochester : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Rosedale : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Valhalla : New York Medical College/Westchester Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
North Carolina
Asheville : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Charlotte : Carolinas Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Durham : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Greenville : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Mooresville : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
New Bern : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Statesville : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Wilmington : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Winston-Salem : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
North Dakota
Fargo : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Grand Forks : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Ohio
Cincinnati : University of Cincinnati, Internal Medicine-Digestive Diseases
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Cleveland : Clinical Investigative Site 00008
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Cleveland : Cleveland Clinic
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Columbus : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Marion : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
Poland : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Toledo : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Willoughby Hills : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Oklahoma
Oklahoma City : INTEGRIS Baptist Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Oklahoma City : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Oklahoma City : Clinical Investigative Site 002
Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)
Oregon
Portland : Orgeon Health & Science University
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Portland : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Roseburg : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Pennsylvania
Beaver : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Bethlehem : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Duncansville : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Philadelphia : Clinical Investigative Site 00003
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Philadelphia : Albert Einstein Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
View More »
Philadelphia : Temple University Hospital
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Philadelphia : University of Pennsylvania
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Philadelphia : Drexel University College of Medicine
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Philadelphia : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Pittsburgh : VA Pittsburgh Healthcare System
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
South Carolina
Anderson : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Columbia : WJB Dorn VA Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Columbia : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Greenville : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Orangeburg : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Tennessee
Bristol : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Dyersburg : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Jackson : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Kingsport : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Knoxville : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
Nashville : Vanderbilt Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Nashville : Clinical Investigative Site 009
Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)
Texas
Arlington : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Austin : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Corsicana : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Dallas : Clinical Investigative Site 000013
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Dallas : UT Southwestern Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
View More »
Dallas : Dallas VA Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Dallas : Baylor University Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Dallas : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Fort Worth : Baylor All Saints Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Fort Worth : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Galveston : The University of Texas Medical Branch at Galveston
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Greenville : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Houston : University of Texas Health Science Center at Houston - Memorial Hermann Hospital
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Houston : St. Luke's Advanced Liver Therapies
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Houston : The Methodist Hospital
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Houston : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Lufkin : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
McAllen : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
San Antonio : University of Texas Health Science Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
San Antonio : Methodist Specialty Transplant Hospital Lab
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
San Antonio : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Utah
Salt Lake City : University of Utah
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Vermont
Burlington : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Virginia
Alexandria : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Charlottesville : Clinical Investigative Site 00001
A Phase 2 Double-Blind, Double-dummy, Multicenter, Prospective, Randomized Study of the Pharmacokinetics of LCP-Tacro Tablets, Once-Daily, Compared to Prograf Capsules, Twice-daily, for the Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Chesapeake : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Fairfax : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Hampton : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
View More »
Manassas : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Mechanicsville : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Norfolk : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Richmond : McGuire DVAMC
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Richmond : Virginia Commonwealth University Health System
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Richmond : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Washington
Seattle : Virginia Mason Medical Center
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Silverdale : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
West Virginia
Bluefield : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Wisconsin
Madison : University of Wisconsin
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Madison : University of Wisconsin - Madison
Renal Blood Flow Measurement With Positron Emission Tomography (PET)
Canada
Montreal : CHUM, Hopital St-Luc
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Toronto : Toronto General Hospital
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Germany
Japan
Chubu :
A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations
Hokkaido :
A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations
Kansai :
A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations
Kantou :
A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations
Kyusyu :
A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations
View More »
Shagoku :
A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations
Shikoku :
A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations
Touhoku :
A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations
Mexico
Tijuana : Hospital Angeles
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Renal Failure
Puerto Rico
Caguas : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Ponce : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Rio Piedras : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
San Juan : Research Site Updated
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Switzerland
Biel/Bienne : Clinic of Internal Medicine, Hospital Center
Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion
